PFE · News · 20261001N

Product / Drug Pipeline Progress

PFIZER INC · 2026-10-01 · Importance 59 · Surprise 82 · In source text

Pfizer’s investigational trispecific antibody tilrekimig (PF-07275315) met the primary endpoint in a Phase 2 trial for adults with moderate-to-severe atopic dermatitis, showing statistically significant EASI-75 responses across all evaluated doses at Week 16. The 200 mg monthly regimen produced a 61.0% EASI-75 response versus 9.1% for placebo. Pfizer is advancing tilrekimig into pivotal Phase 3 atopic dermatitis trials, including a head-to-head study against dupilumab, while also testing it in asthma and a Phase 2b/3 COPD study. The program targets type 2 inflammation and expands Pfizer’s inflammation and immunology pipeline.

Key facts

• Pfizer is advancing tilrekimig into pivotal Phase III trials for atopic dermatitis and asthma following positive Phase II data. source
• Pfizer has already initiated two Phase 3 studies for atopic dermatitis, including one directly comparing tilrekimig with dupilumab. source
• Pfizer is conducting a Phase IIb/III study for tilrekimig in COPD. source
• Pfizer presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. source
• The Phase 2 study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. source
• In the Phase 2 atopic dermatitis study, Pfizer reported 61.0% EASI-75 for patients receiving a monthly 200 mg dose compared to 9.1% on placebo. source
• In the Phase 2 atopic dermatitis study, Pfizer reported 61.00 percent EASI-75 at Week 16 for the 200 mg monthly dose. source

Impact estimates